Depemokimab: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
Depemokimab: clinical details
Prescribing considerations
- Prescribing should be undertaken by clinicians experienced in diagnosing and treating asthma or chronic rhinosinusitis with nasal polyps.
- Confirm that licensed disease, age and background-treatment criteria are met.
- Do not use for acute asthma symptoms or an acute exacerbation; continue appropriate background treatment.
- Treat pre-existing helminth infection before initiation. If infection develops and does not respond to treatment, consider postponing further administration until resolved.
- Record the product name and batch number for biological traceability.
Contraindications and cautions
- Hypersensitivity to depemokimab or any excipient.
- Use caution with previous systemic reactions to injected medicines and because polysorbate 80 may cause allergic reactions.
Monitoring
- Review disease control, exacerbations and worsening after treatment begins.
- Monitor for immediate or delayed hypersensitivity and reassess suitability after a reaction.
- Review helminth-infection risk, including relevant residence or travel.
- Supervise any reduction in background corticosteroids.
- Report suspected adverse reactions through the MHRA Yellow Card scheme, including brand and batch number where available.
Clinical pharmacology
Depemokimab is a humanised IgG1 kappa antibody against interleukin-5. Fc-region modification increases neonatal Fc-receptor binding and extends persistence. It is slowly absorbed after subcutaneous injection and degraded through general proteolytic pathways rather than renal clearance.
Formulation and product differences
- A single-use pre-filled glass syringe with a fixed needle and passive safety needle guard.
- The solution is clear to opalescent and may be colourless to yellow-brown; cloudiness, abnormal discolouration or particles make it unsuitable for use.
Depemokimab preparations and strengths
Injection
Route: Parenteral
Strengths: 100 mg
Depemokimab interactions
Formal interaction studies have not been conducted, so all current and recently used products should be reviewed.
Systemic or inhaled corticosteroids
Do not stop them abruptly after starting depemokimab; any reduction should be gradual and medically supervised.
Other prescribed, non-prescribed or herbal products
No specific interactions are established, but tell the prescriber about all products used.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.